RecruitingMarginal Zone Lymphoma
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
Sponsor: University of Utah
You may qualify if…
- ✓ Subjects aged ≥ 18 years.
- ✓ ECOG Performance Status ≤ 2.
- ✓ Histologically confirmed marginal zone lymphoma, including splenic, nodal, and extranodal sub-types per the enrolling institution.
- ✓ Subjects must have an indication for treatment.
- ✓ No prior systemic therapy for MZL except for the following:
- ✓ Prior antibiotic therapy for H. pylori, C. psittaci, and B. burgdorferi
- ✓ Prior antiviral therapy for HCV
- ✓ --Note: Subjects are eligible if they had a prior splenectomy or other local surgical treatment or local radiation therapy without systemic therapy and now require their first ever systemic therapy. In the event of the receipt of radiation therapy, the minimum washout period is 14 days
You may not qualify if…
- ✕ Subjects requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.
- ✕ Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
- ✕ Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug.
- ✕ History of bleeding diathesis
- ✕ Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.
- ✕ The diagnosis of another malignancy which is, in the opinion of the investigator, likely to negatively impact study participation or subject safety.
- ✕ Subjects with CNS involvement
- ✕ Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:
Where it's recruiting
Source: ClinicalTrials.gov · NCT06390956 · last updated 2025-12-04